Isodiol International Inc. announced that it has signed a letter of intent (LOI) with Nuuvera Holdings Limited. Isodiol and Nuuvera have agreed to import 99%+ pure, bioactive pharma-grade cannabidiol ('CBD') isolate into Canada from Isodiol's GMP-certified production facility in the United Kingdom. The product, certified as a pharmaceutical-grade, will be imported into Canada through Nuuvera's subsidiary, ARA-Avanti Rx Analytics Inc. ("Avanti"), a Health Canada GMP-certified laboratory holding a dealer license under the Narcotic Control Regulations and Office of Controlled Substances. Under the LOI terms, Nuuvera will import to Canada a Isodiol's CBD isolate and conduct analytical testing in its Toronto-area laboratory to ensure that the product conforms to Isodiol's rigorous product specifications. Nuuvera intends, ultimately, to import up to 30,000 kg of CBD isolate per month for the purposes of R&D, product formulation and production of pharma-grade derivative products. Through its licensed subsidiaries, Nuuvera intends to then sell such products in Canada and via export to appropriately licensed international medical cannabis jurisdictions. Upon successful initial import and product testing, Nuuvera and Isodiol intend to execute a Definitive Supply Agreement, the terms of which are already substantively agreed upon. The activities contemplated by the LOI remain subject to applicable regulatory approvals, including those from Health Canada and the TSX Venture Exchange.